2024 Chris astle zymeworks

Chris astle zymeworks

Author: ovbd

August undefined, 2024

WebMay 4, 2024 · VANCOUVER, British Columbia, May 04, 2024 -- ( BUSINESS WIRE )--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported... WebChris Astle is Sr VP/CFO at Zymeworks Inc. See Chris Astle's compensation, career history, education, & memberships.

Zymeworks Provides Corporate Update and Reports Year-End

WebZymeworks is headquartered in Vancouver, British Columbia, Canada. Headquarters United States of America Address 108 Patriot Drive, Suite A, Middletown, Delaware, 19709 Website www.zymeworks.com Telephone 1 302 2748744 No of Employees 284 Industry Pharmaceuticals and Healthcare Ticker Symbol & Exchange ZYME (NYSE) WebZymeworks Inc (Zymeworks) is a clinical stage biopharmaceutical company that discovers, develops and commercializes biotherapeutics for the treatment of cancer, autoimmune … cvip digital

Christopher W. Steinle, Architect

WebDr. Astle joined Zymeworks in April 2024 and currently serves as Senior Vice President and Chief Financial Officer. Prior to joining Zymeworks, Dr. Astle worked as a Chief … WebChris brings a wealth of finance experience… 16 comments on LinkedIn Zymeworks Inc. on LinkedIn: We are thrilled to announce the promotion of Dr. Chris Astle to Senior… 16 comments Skip to ... WebOct 8, 2024 · Chris Astle Chief Financial Officer at Zymeworks Published Oct 8, 2024 + Follow CFOs are now contributing more than ever to corporate strategy in all sizes of organisation Published by... cvip proda login

Chris Astle, P.Eng, PMP - Program Manager - Bruce Power LinkedIn

Chris astle zymeworks

Zymeworks Provides Corporate Update and Reports Third …

WebApr 12, 2024 · Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. About the company Rewards Price-To-Earnings ratio (4.8x) is below the US market (14.8x) Became profitable this year Risk Analysis WebNov 8, 2024 · “With the anticipated proceeds from our exclusive licensing agreement with Jazz, our significantly improved financial position allows Zymeworks to properly fund and advance exciting opportunities in our product pipeline,” said Chris Astle, Ph.D., SVP and Chief Financial Officer.

Did you know?

http://www.christophersteinle.com/ WebMar 8, 2024 · Zymeworks Inc. ( NASDAQ: ZYME) Q4 2024 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Jack Spinks - Head of Investor …

WebFeb 24, 2024 · Dr. Astle joined Zymeworks in April 2024 and has served as its Executive Director, Corporate and Commercial Finance from April 2024 to February 2024. Prior to … WebMay 4, 2024 · Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody ...

WebMar 7, 2024 · VANCOUVER, British Columbia, March 07, 2024--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial... WebNov 14, 2024 · Chris Astle Chief Financial Officer at Zymeworks View articles by Chris Astle The CFO as strategist: from SMEs to… October 8, 2024 32 likes1 comment The …

WebFeb 24, 2024 · Chris joined the finance group at Zymeworks in 2024 after relocating from Seattle where he previously served as Vice President at Alder Pharmaceuticals (sold to Lundbeck in 2024 for $1.6...

WebZymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. cvip login prodaWebDec 31, 2024 · Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional … raiden mk.4WebNov 8, 2024 · Zymeworks is eligible to receive a $50 million upfront payment, ... financial position allows Zymeworks to properly fund and advance exciting opportunities in our product pipeline,” said Chris Astle, Ph.D., SVP and Chief Financial Officer. “With our cash runway potentially extended through at least 2026, and potentially beyond, we can focus ... raiden mk1WebFeb 24, 2024 · Chris joined the finance group at Zymeworks in 2024 after relocating from Seattle where he previously served as Vice President at Alder Pharmaceuticals (sold to … raiden mk 11WebFeb 28, 2024 · I am excited to share that I have joined the board of Oak Bay Biosciences, Inc. to support their launch and Angel investment round, and beyond to their… cvinzWebFeb 24, 2024 · Chris joined the finance group at Zymeworks in 2024 after relocating from Seattle where he previously served as Vice President at Alder Pharmaceuticals (sold to … raiden mmdWebMay 4, 2024 · Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. raiden mp3